wire - news in brief
Category
Results 301 - 350 of 355.
Novartis announces Lancet publication of pioneering study in migraine prevention showing efficacy of Aimovig where other treatments have failed
The LIBERTY trial is the first study of a CGRP-targeted therapy in a patient population where multiple preventive treatments had previously failed Patients treated with Aimovig, reported significan
The LIBERTY trial is the first study of a CGRP-targeted therapy in a patient population where multiple preventive treatments had previously failed Patients treated with Aimovig, reported significan
Roche’s Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-squamous non-small cell lung cancer live significantly longer compared to chemotherapy alone
Roche's Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-squamous non-small cell lung cancer live significantly longer compared to chemot
Roche's Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-squamous non-small cell lung cancer live significantly longer compared to chemot
Novartis COMBI-AD study of Tafinlar + Mekinist continues to demonstrate relapse free survival benefit in patients with BRAF V600-mutant stage III melanoma
Extended follow up results confirm leading BRAF/MEK inhibitor combination Tafinlar + Mekinist continues to show relapse free survival benefit Cure rate modeling which estimates fraction of patients
Extended follow up results confirm leading BRAF/MEK inhibitor combination Tafinlar + Mekinist continues to show relapse free survival benefit Cure rate modeling which estimates fraction of patients
Roche’s investigational personalised medicine entrectinib shrank tumours in people with NTRK fusion-positive solid tumours
Entrectinib showed response irrespective of tumour type or spread to the central nervous system (CNS) Data will be submitted to global regulatory authorities, including the US Food and Drug Administr
Entrectinib showed response irrespective of tumour type or spread to the central nervous system (CNS) Data will be submitted to global regulatory authorities, including the US Food and Drug Administr
Roche’s Tecentriq in combination with Abraxane improves outcomes as an initial treatment for people with PD-L1-positive metastatic triple-negative breast cancer
Tecentriq combination first immunotherapy regimen to demonstrate positive Phase III results in breast cancer Tecentriq and nab -paclitaxel significantly reduced the risk of disease worsening or death in both the intention-to-treat and PD-L1-positive populations Clinically meaningful overall survival improvement in the PD-L1-positive population at this interim analysis Data are being presented at the European Society for Medical Oncology (ESMO) 2
Tecentriq combination first immunotherapy regimen to demonstrate positive Phase III results in breast cancer Tecentriq and nab -paclitaxel significantly reduced the risk of disease worsening or death in both the intention-to-treat and PD-L1-positive populations Clinically meaningful overall survival improvement in the PD-L1-positive population at this interim analysis Data are being presented at the European Society for Medical Oncology (ESMO) 2
Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC
Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC Phase II study efficacy data showed overall response rate of 72.0% and 39.1%, respectively, in treatment-naive and previously treated patients with advanced MET exon-14 skipping mutated non-small cell lung cancer (NSCLC) Clinical findings from ongoing study indicate safety prof
Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC Phase II study efficacy data showed overall response rate of 72.0% and 39.1%, respectively, in treatment-naive and previously treated patients with advanced MET exon-14 skipping mutated non-small cell lung cancer (NSCLC) Clinical findings from ongoing study indicate safety prof
Novartis announces presentation of new Lutathera NETTER-1 data
Novartis announces presentation of new Lutathera NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden Lutathera treatment was associated with a
Novartis announces presentation of new Lutathera NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden Lutathera treatment was associated with a
Architect Bernard Tschumi has donated the archives of his Bridge City project - developed for the City of Lausanne in 1988 - to EPFL.
One Health: Working together for human and animal health
Bern, 18.10.2018 - Prevention and early detection are central to effective control of communicable diseases and their vectors, such as mosquitoes.
Bern, 18.10.2018 - Prevention and early detection are central to effective control of communicable diseases and their vectors, such as mosquitoes.
Modifying a virtual environment in just a few clicks
Creating and modifying a virtual reality environment just got a lot easier thanks to software being released today by Imverse, an EPFL spin-off.
Creating and modifying a virtual reality environment just got a lot easier thanks to software being released today by Imverse, an EPFL spin-off.
Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx leadership in spondyloarthritis
Data from the MEASURE 1 and FUTURE 1 studies show rapid and long-lasting sustained improvement in the signs and symptoms of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) , In rheumatolo
Data from the MEASURE 1 and FUTURE 1 studies show rapid and long-lasting sustained improvement in the signs and symptoms of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) , In rheumatolo
Roche’s Kadcyla reduced the risk of disease recurring in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Phase III KATHERINE study shows Kadcyla significantly improved invasive disease-free survival compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment Data will be submitted to health authorities around the world, including the US Food and Drug Administration and European Medicines Agency Results will be presented at the 2018 San Antonio Breast Cancer Symposium in December Roche tod
Phase III KATHERINE study shows Kadcyla significantly improved invasive disease-free survival compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment Data will be submitted to health authorities around the world, including the US Food and Drug Administration and European Medicines Agency Results will be presented at the 2018 San Antonio Breast Cancer Symposium in December Roche tod
Empa and BeAM, a manufacturer of machines for metal 3D printing, are glad to announce an extensive research and development agreement.
EPFL scientists will soon be heading off to Antarctica, where they will spend four months collecting reams of meteorological data at Australia's Davis research station.
Novartis announces new data from the first direct head-to-head trial to demonstrate superior efficacy of Gilenya over Copaxone in patients with relapsing remitting multiple sclerosis
Topline findings from ASSESS show adult relapsing remitting multiple sclerosis (RRMS) patients taking Gilenya (fingolimod) 0.5mg experienced significantly fewer relapses than patients on Copaxone (glatiramer acetate) 20mg Gilenya 0.5mg is the first and only disease modifying therapy to show superiority in reducing relapses vs Copaxone in a controlled, head-to-head trial Treatment discontinuations were overall more common in the
Topline findings from ASSESS show adult relapsing remitting multiple sclerosis (RRMS) patients taking Gilenya (fingolimod) 0.5mg experienced significantly fewer relapses than patients on Copaxone (glatiramer acetate) 20mg Gilenya 0.5mg is the first and only disease modifying therapy to show superiority in reducing relapses vs Copaxone in a controlled, head-to-head trial Treatment discontinuations were overall more common in the
Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study
Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study Data published in the American Journal of Hematology show more than twice as many patients taking crizanlizumab did not experience a disease-related pain crisis (also called vaso-occlusive crisis, or VOC) vs placebo VOCs are the most common, painful complication of sickle cell disease and the main reas
Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study Data published in the American Journal of Hematology show more than twice as many patients taking crizanlizumab did not experience a disease-related pain crisis (also called vaso-occlusive crisis, or VOC) vs placebo VOCs are the most common, painful complication of sickle cell disease and the main reas
Summit in the field of Additive Manufacturing
Empa underscores its leading role in the exchange of knowledge in the field of Additive Manufacturing (AM).
Empa underscores its leading role in the exchange of knowledge in the field of Additive Manufacturing (AM).
Additive Manufacturing summit
Empa underscores its leading role in the exchange of knowledge in the field of Additive Manufacturing (AM).
Empa underscores its leading role in the exchange of knowledge in the field of Additive Manufacturing (AM).
Novartis announces FDA and EMA filing acceptance of siponimod, the first and only drug shown to meaningfully delay disability progression in typical SPMS patients
There is a critical need for safe and effective treatments for secondary progressive multiple sclerosis (SPMS) - a highly debilitating form of MS characterized by gradual, irreversible worsening of d
There is a critical need for safe and effective treatments for secondary progressive multiple sclerosis (SPMS) - a highly debilitating form of MS characterized by gradual, irreversible worsening of d
Congratulations to the FMI Prize winners 2018
As in previous years, several internal prizes were awarded during the FMI Annual Meeting, a 3 day scientific meeting attended by most scientists in the institute.
As in previous years, several internal prizes were awarded during the FMI Annual Meeting, a 3 day scientific meeting attended by most scientists in the institute.
Even Small Gifts Boost Business
The offering of a gift - a sign of gratitude for a good business relationship, or a bribe? It's a fine line that is often hard to judge.
The offering of a gift - a sign of gratitude for a good business relationship, or a bribe? It's a fine line that is often hard to judge.
Positive phase III results for baloxavir marboxil in people at high risk of complications from influenza to be presented at IDWeek 2018
Baloxavir marboxil - a first-in-class, single-dose, investigational oral medicine - is the first potential influenza treatment in clinical trials to demonstrate a clinically meaningful benefit for people highly vulnerable to serious influenza complications CAPSTONE-2 showed that baloxavir marboxil significantly reduced time to improvement of influenza symptoms versus placebo Influenza, or ‘flu', results in millions of debilitating illnesse
Baloxavir marboxil - a first-in-class, single-dose, investigational oral medicine - is the first potential influenza treatment in clinical trials to demonstrate a clinically meaningful benefit for people highly vulnerable to serious influenza complications CAPSTONE-2 showed that baloxavir marboxil significantly reduced time to improvement of influenza symptoms versus placebo Influenza, or ‘flu', results in millions of debilitating illnesse
FDA approves Roche’s Hemlibra for haemophilia A without factor VIII inhibitors
First medicine to significantly reduce treated bleeds compared to prior factor VIII prophylaxis based on an intra-patient comparison Only medicine that can be self-administered subcutaneously once we
First medicine to significantly reduce treated bleeds compared to prior factor VIII prophylaxis based on an intra-patient comparison Only medicine that can be self-administered subcutaneously once we
Sandoz Healthcare Access Challenge (HACk) returns, seeking digital solutions to local healthcare access challenges
Despite major advances in modern medicine, universal access to healthcare remains the largest unmet medical need Building on the inaugural Sandoz HACk, this year's competition expands to seek broader
Despite major advances in modern medicine, universal access to healthcare remains the largest unmet medical need Building on the inaugural Sandoz HACk, this year's competition expands to seek broader
Roche announces new data for risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress
Roche announces new data for risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress Preliminary findings from Part 1 of the FIREFISH study show that infants with Type 1 SMA are meeting developmental milestones including sitting without support Preliminary data from Part 1 of the SUNFISH study show improvements in motor function in people with Type 2/3 SMA No drug-related safety findings leading to withdrawal in risdiplam
Roche announces new data for risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress Preliminary findings from Part 1 of the FIREFISH study show that infants with Type 1 SMA are meeting developmental milestones including sitting without support Preliminary data from Part 1 of the SUNFISH study show improvements in motor function in people with Type 2/3 SMA No drug-related safety findings leading to withdrawal in risdiplam
Jacques Lévy has been awarded the 2018 Vautrin-Lud Prize, a geography award modeled on the Nobel Prize.
Novartis licenses three novel anti-infective programs to Boston Pharmaceuticals
Clinical and pre-clinical stage programs focused on addressing growing need for new treatments against drug resistant Gram-negative bacteria Agreement is part of Novartis strategy to partner with l
Clinical and pre-clinical stage programs focused on addressing growing need for new treatments against drug resistant Gram-negative bacteria Agreement is part of Novartis strategy to partner with l
Empa is expanding its Coating Competence Center (CCC) thanks to a new partnership in the field of printed electronics with US-based equipment manufacturer Optomec.
On September 30, 2016, the active phase of the ESA's Rosetta mission came to an end with the controlled crash landing of the probe on the surface of the comet Chury.
Fructose metabolism and noncommunicable diseases: recent findings and new research perspectives
Prof. Luc Tappy, Department of Physiology Fructose is a physiological nutrient which, when consumed in excess, may have adverse metabolic effects, mainly in the liver (hepatic insulin resistance and fat storage).
Prof. Luc Tappy, Department of Physiology Fructose is a physiological nutrient which, when consumed in excess, may have adverse metabolic effects, mainly in the liver (hepatic insulin resistance and fat storage).